2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Jorda MA et al. Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. 2003 Ann. N. Y. Acad. Sci. pmid:12799277
Walter L and Stella N Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. 2003 Glia pmid:12951660
Wallace MJ et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. 2003 J. Pharmacol. Exp. Ther. pmid:12954810
Vannacci A et al. Nitric oxide modulates the inhibitory effect of cannabinoids on the immunological activation of guinea pig mast cells. 2003 Inflamm. Res. pmid:12755386
Kishimoto S et al. 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. 2003 J. Biol. Chem. pmid:12711605
Maccarrone M et al. Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. 2003 Thromb. Haemost. pmid:12574815
Bouchard JF et al. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. 2003 Life Sci. pmid:12586223
Higgs S et al. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. 2003 Psychopharmacology (Berl.) pmid:12447606
Bisogno T et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. 2003 J. Cell Biol. pmid:14610053
Facchinetti F et al. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. 2003 Glia pmid:12509806
Kim J and Alger BE Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. 2004 Nat. Neurosci. pmid:15184902
Witting A et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. 2004 J. Neurochem. pmid:15189359
Stanke-Labesque F et al. 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. 2004 Cardiovasc. Res. pmid:15194472
Oka S et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. 2004 J. Leukoc. Biol. pmid:15316028
Nithipatikom K et al. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. 2004 Cancer Res. pmid:15604240
González S et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. 2004 Drug Alcohol Depend pmid:15099659
Valenti M et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. 2004 Cell. Mol. Life Sci. pmid:15095014
Kishimoto S et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. 2004 J. Biochem. pmid:15115777
Hájos N et al. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. 2004 Eur. J. Neurosci. pmid:15182306
Vannacci A et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. 2004 J. Pharmacol. Exp. Ther. pmid:15187170
Maestroni GJ The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. 2004 FASEB J. pmid:15385435
Walter L et al. ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. 2004 J. Neurosci. pmid:15371507
Dinh TP et al. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. 2004 Mol. Pharmacol. pmid:15272052
Malorni W et al. Morphological evidence that 2-arachidonoylglycerol is a true agonist of human platelets. 2004 Thromb. Haemost. pmid:15543349
Melis M et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. 2004 J. Neurosci. pmid:15564588
Sugiura T et al. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. 2004 J. Pharmacol. Sci. pmid:15599096
Saario SM et al. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. 2004 Biochem. Pharmacol. pmid:15013854
Alberich Jordà M et al. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. 2004 Blood pmid:15039279
Witting A et al. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:14976257
Carrier EJ et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. 2004 Mol. Pharmacol. pmid:15044630
Golech SA et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. 2004 Brain Res. Mol. Brain Res. pmid:15548432
Mukherjee S et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. 2004 Eur. J. Pharmacol. pmid:15556131
Guo J and Ikeda SR Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. 2004 Mol. Pharmacol. pmid:14978245
Piomelli D The endogenous cannabinoid system and the treatment of marijuana dependence. 2004 Neuropharmacology pmid:15464150
Ghafouri N et al. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. 2004 Br. J. Pharmacol. pmid:15492019
Motobe T et al. Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. 2004 Shock pmid:14676677
Hayase T et al. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. 2005 Behav Pharmacol pmid:16148444
Sancho R et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. 2005 J. Immunol. pmid:16148147
Lauckner JE et al. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. 2005 Proc. Natl. Acad. Sci. U.S.A. pmid:16365309
Gokoh M et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. 2005 FEBS Lett. pmid:16288744
Straiker A and Mackie K Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. 2005 J. Physiol. (Lond.) pmid:16179366
Iturralde M et al. Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. 2005 Apoptosis pmid:16215685
Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. 2005 Diabetes pmid:16186383
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Alger BE Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. 2005 Sci. STKE pmid:16278487
Rademacher DJ et al. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). 2005 Neurotoxicology pmid:15527869
Di S et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. 2005 J. Physiol. (Lond.) pmid:16239276
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
McPartland JM et al. Cannabimimetic effects of osteopathic manipulative treatment. 2005 J Am Osteopath Assoc pmid:16118355
Wahn H et al. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:16055511